We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A practical review on carfilzomib in multiple myeloma.
- Authors
Muchtar, Eli; Gertz, Morie A.; Magen, Hila
- Abstract
Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma ( MM) since its approval by the American food and drug administration ( FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.
- Subjects
MULTIPLE myeloma treatment; ANTINEOPLASTIC agents; CANCER relapse; PROTEASOME inhibitors; CLINICAL trials
- Publication
European Journal of Haematology, 2016, Vol 96, Issue 6, p564
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.12749